Experimental feature

Listen to this article

00:00
00:00
Experimental feature

Hikma Pharmaceuticals is topping the FTSE All Share this morning after the company reported better than expected results for 2016.

The generic drug specialist earlier said that a fall in operating profits last year was not as bad as expected, while revenues were a touch better than expectations.

Hikma also slightly raised its dividend for last year and predicted revenue growth of 10 per cent in 2017.

Get alerts on Hikma Pharmaceuticals PLC when a new story is published

Copyright The Financial Times Limited 2018. All rights reserved.

Comments have not been enabled for this article.

Follow the topics in this article